Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ⅲ Clinical Study to Evaluate the Safety and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine (PCV13) in Healthy Infants

NCT06617715 is registered in ClinicalTrials.gov with Sinovac Life Sciences Co., Ltd. as lead sponsor.

NCT NCT06617715
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06617715 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ⅲ Clinical Study to Evaluate the Safety and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine (PCV13) in Healthy Infants
Lead sponsor
Sinovac Life Sciences Co., Ltd.
Phase
Phase 3
Overall status
Recruiting
Start date
October 23, 2024
Completion date
July 30, 2026
Enrollment
3,080 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pneumococcal infectious disease